How should I use Koselugo(Selumetinib)?

KOSELUGO dosing is individualized based on body surface area and clinical context.

Individualized Dosing Regimen for KOSELUGO

The recommended dosage of KOSELUGO (selumetinib) for pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas is 25 mg/m² administered orally twice daily, approximately every 12 hours. Dosing is adjusted according to body surface area, with specific dose bands provided in the prescribing information. Dose modifications are required for patients with moderate hepatic impairment (Child-Pugh B), reducing the dose to 20 mg/m² twice daily. Further dose adjustments are necessary in the event of adverse reactions or drug interactions, particularly with CYP3A4 inhibitors or inducers. Administration in patients unable to swallow capsules is not recommended.

Related Columns

Selumetinib(Koselugo)

KOSELUGO (selumetinib) is indicated for the treatment of pediatric patients...

WeChat Scan
Free Inquiry

How to Use Selumetinib (Koselugo)

Selumetinib (Koselugo) is a MEK1/2 kinase inhibitor that plays a key role in the treatment of symptomatic, inoperable plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) in chi...

Dosage Overview: Selumetinib

Selumetinib is a targeted drug specifically designed for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). This article will provide a detailed description ...

Selumetinib dosage

Selumetinib(Koselugo) has demonstrated significant clinical efficacy as a kinase inhibitor in pediatric patients with neurofibromatosis type 1 (NF1) who are 2 years of age and older with symptomatic, ...